SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Proteon Therapeutics, Inc. (NASDAQ CM: PRTO)

BALA CYNWYD, October 18, 2019 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Proteon Therapeutics, Inc. (“Proteon” or “the Company”) (NASDAQ CM:PRTO) for possible breaches of fiduciary duty and other violations of federal and state law in connection with proposed acquisition of the Company by ArTara Therapeutics, Inc. (“ArTara”). Under the terms of the agreement, Under the terms of the merger agreement, current Proteon stockholders will own only approximately 10% of the combined company, while ArTara holders will own approximately 90%.

The investigation concerns whether the Proteon Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether ArTara is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many Proteon shareholders. For example, the 52-week high for the Company’s stock was over $3.90.

If you own shares of Proteon stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.